RU2005123801A - Агенты для диагностической визуализации, обладающие ингибирующей активностью в отношении матриксных металлопротеиназ (ммро) - Google Patents
Агенты для диагностической визуализации, обладающие ингибирующей активностью в отношении матриксных металлопротеиназ (ммро) Download PDFInfo
- Publication number
- RU2005123801A RU2005123801A RU2005123801/15A RU2005123801A RU2005123801A RU 2005123801 A RU2005123801 A RU 2005123801A RU 2005123801/15 A RU2005123801/15 A RU 2005123801/15A RU 2005123801 A RU2005123801 A RU 2005123801A RU 2005123801 A RU2005123801 A RU 2005123801A
- Authority
- RU
- Russia
- Prior art keywords
- agent
- diagnostic imaging
- emitting
- formula
- group
- Prior art date
Links
- 102000002274 Matrix Metalloproteinases Human genes 0.000 title claims 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 title claims 3
- 238000012800 visualization Methods 0.000 title claims 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 238000002059 diagnostic imaging Methods 0.000 claims 20
- 239000003795 chemical substances by application Substances 0.000 claims 14
- 239000003446 ligand Substances 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000002184 metal Substances 0.000 claims 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 239000012216 imaging agent Substances 0.000 claims 5
- 229910052740 iodine Inorganic materials 0.000 claims 5
- 239000011630 iodine Substances 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 230000002285 radioactive effect Effects 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 239000002738 chelating agent Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 239000002243 precursor Substances 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims 2
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 150000003456 sulfonamides Chemical group 0.000 claims 2
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001499 aryl bromides Chemical class 0.000 claims 1
- 150000001503 aryl iodides Chemical class 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- 150000004696 coordination complex Chemical class 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- -1 hydroxy, methyl Chemical group 0.000 claims 1
- 125000006289 hydroxybenzyl group Chemical group 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 1
- 150000004654 triazenes Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0302891.7 | 2003-02-10 | ||
| GB0302891A GB0302891D0 (en) | 2003-02-10 | 2003-02-10 | Diagnostic imaging agents for cardiovascular disease |
| GB0307524A GB0307524D0 (en) | 2003-04-01 | 2003-04-01 | Diagnostic imaging agents with MMP inhibitory activity |
| GB0307524.9 | 2003-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005123801A true RU2005123801A (ru) | 2006-03-27 |
Family
ID=32852413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005123801/15A RU2005123801A (ru) | 2003-02-10 | 2004-02-10 | Агенты для диагностической визуализации, обладающие ингибирующей активностью в отношении матриксных металлопротеиназ (ммро) |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8231858B2 (enExample) |
| EP (1) | EP1592458A1 (enExample) |
| JP (1) | JP2006519216A (enExample) |
| AU (1) | AU2004210208B2 (enExample) |
| CA (1) | CA2514885A1 (enExample) |
| NO (1) | NO20053776L (enExample) |
| RU (1) | RU2005123801A (enExample) |
| WO (1) | WO2004069365A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0326546D0 (en) * | 2003-11-14 | 2003-12-17 | Amersham Plc | Inhibitor imaging agents |
| GB0421308D0 (en) * | 2004-09-24 | 2004-10-27 | Amersham Plc | Enzyme inhibitor imaging agents |
| US8986650B2 (en) | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
| JP5368099B2 (ja) | 2005-10-07 | 2013-12-18 | ゲルベ | ガリウムと錯体形成することが可能なシグナル部分にカップリングされた、生物学的標的の認識のための部分を含んでなる化合物 |
| CA2913373C (en) | 2006-10-06 | 2017-11-07 | Mallinckrodt Llc | Self-aligning radioisotope elution system |
| EP2149568A1 (en) | 2008-07-22 | 2010-02-03 | Bracco Imaging S.p.A | Aryl-sulphonamidic dimers as metalloproteases inhibitors |
| EP2147684A1 (en) * | 2008-07-22 | 2010-01-27 | Bracco Imaging S.p.A | Diagnostic Agents Selective Against Metalloproteases |
| US9153350B2 (en) | 2011-01-19 | 2015-10-06 | Mallinckrodt Llc | Protective shroud for nuclear pharmacy generators |
| US8866104B2 (en) | 2011-01-19 | 2014-10-21 | Mallinckrodt Llc | Radioisotope elution system |
| US8809804B2 (en) * | 2011-01-19 | 2014-08-19 | Mallinckrodt Llc | Holder and tool for radioisotope elution system |
| WO2013010573A1 (en) * | 2011-07-18 | 2013-01-24 | Universitaet Muenster | Compounds with matrix-metalloproteinase inhibitory activity |
| US9023318B2 (en) * | 2011-06-08 | 2015-05-05 | Siemens Medical Solutions Usa, Inc. | Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof |
| EP2775906B1 (en) | 2011-11-11 | 2019-07-03 | Yale University | Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging |
| EP2644601A1 (en) * | 2012-03-28 | 2013-10-02 | Westfälische Wilhelms-Universität Münster | Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof |
| GB202012671D0 (en) * | 2020-08-13 | 2020-09-30 | Nrf Ithemba Labs | Theranostic Compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4427646A (en) * | 1981-04-02 | 1984-01-24 | Research Corporation | Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo |
| US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
| TW453995B (en) * | 1995-12-15 | 2001-09-11 | Novartis Ag | Certain alpha-substituted arylsulfonamido acetohydroxamic acids |
| AU7294098A (en) * | 1997-05-09 | 1998-11-27 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| US6656448B1 (en) * | 2000-02-15 | 2003-12-02 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
| US6989139B2 (en) * | 2000-02-15 | 2006-01-24 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
| AU2001265182A1 (en) * | 2000-05-30 | 2001-12-11 | Rafael Fridman | Inhibitors of matrix metalloproteinases |
-
2004
- 2004-02-10 US US10/544,945 patent/US8231858B2/en not_active Expired - Fee Related
- 2004-02-10 RU RU2005123801/15A patent/RU2005123801A/ru not_active Application Discontinuation
- 2004-02-10 WO PCT/GB2004/000524 patent/WO2004069365A1/en not_active Ceased
- 2004-02-10 CA CA002514885A patent/CA2514885A1/en not_active Abandoned
- 2004-02-10 EP EP04709657A patent/EP1592458A1/en not_active Withdrawn
- 2004-02-10 JP JP2006502261A patent/JP2006519216A/ja active Pending
- 2004-02-10 AU AU2004210208A patent/AU2004210208B2/en not_active Ceased
-
2005
- 2005-08-09 NO NO20053776A patent/NO20053776L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004069365A1 (en) | 2004-08-19 |
| CA2514885A1 (en) | 2004-08-19 |
| EP1592458A1 (en) | 2005-11-09 |
| JP2006519216A (ja) | 2006-08-24 |
| WO2004069365A8 (en) | 2004-09-30 |
| AU2004210208B2 (en) | 2007-06-07 |
| NO20053776D0 (no) | 2005-08-09 |
| AU2004210208A1 (en) | 2004-08-19 |
| US8231858B2 (en) | 2012-07-31 |
| US20070071670A1 (en) | 2007-03-29 |
| NO20053776L (no) | 2005-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005123801A (ru) | Агенты для диагностической визуализации, обладающие ингибирующей активностью в отношении матриксных металлопротеиназ (ммро) | |
| TWI267381B (en) | Stilbene derivatives and their use for binding and imaging amyloid plaques | |
| CA1253799A (en) | Nmr contrast agents | |
| RU2008150377A (ru) | Новое соединение, обладающее сродством к амилоиду | |
| US10155053B2 (en) | Method for obtaining novel derivatives of naphthalene for the in vivo diagnosis of Alzheimer's disease | |
| JP2004516314A5 (enExample) | ||
| US5089249A (en) | Conjugates for bone imaging and bone cancer therapy | |
| CA2440794A1 (en) | Neurofibrillary labels | |
| BRPI0710225B1 (pt) | Derivados e composições de estirilpiridina compreendendo os mesmos | |
| AR044294A1 (es) | N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa | |
| KR880009917A (ko) | 에스테르-치환된 디아민티올 및 그의 방사성 표지된 착화합물 | |
| RU2006107563A (ru) | Зонды для заболеваний с накоплением амилоида, красители для амилоида, лекарства для лечения и профилактики заболеваний с накоплением амилоида, зонды для диагностики нейрофибриллярных клубков и красители для нейрофибриллярных клубков | |
| JP2006519216A5 (enExample) | ||
| RU2006117298A (ru) | Визуализирующие агенты на основе ингибитора | |
| KR910018346A (ko) | 킬레이트화 화합물 및 그의 용도 | |
| NZ577458A (en) | Acetylene derivatives and their use for binding and imaging amyloid plaques | |
| CA2506296A1 (en) | Water-soluble anionic bacteriochlorophyll derivatives and their uses | |
| RU2008126463A (ru) | Связывающие амилоид бензотиазоловые соединения (варианты), фармацевтическая композиция на их основе, способ детекции отложений амилоида (варианты), способ отличения пораженного болезнью альцгеймера мозга от нормального, способ измерения количества амилоида, способ избирательного связывания с амилоидными бляшками (варианты) и способ выявления продромальной стадии заболевания, связанного с отложениями амилоида с их помощью | |
| JPS5925397A (ja) | 心筋イメ−ジ剤および方法 | |
| RU2005131872A (ru) | Производные бензотиазола (варианты), фармацевтическая композиция для детекции отложений амилоида и способ их детекции у млекопитающего | |
| RU2007110372A (ru) | Агенты визуализации, ингибирующие металлопротеиназу | |
| RU2018132050A (ru) | Антагонисты рецепторов соматостатина и способы их применения | |
| CA2056662A1 (en) | Naphthoic acid derivative | |
| US5202109A (en) | Conjugates for bone imaging and bone cancer therapy | |
| Iikuni et al. | Synthesis and biological evaluation of novel technetium-99m-labeled phenylquinoxaline derivatives as single photon emission computed tomography imaging probes targeting β-amyloid plaques in Alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080915 |